Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 3 completed trials

    Completion Rate
    100%(3/3)
    Active Trials
    0(0%)
    Results Posted
    33%(1 trials)

    Phase Distribution

    Phase 2
    1
    25%
    Phase 4
    3
    75%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    3

    Late Stage

    Phase Distribution4 total trials
    Phase 2Efficacy & side effects
    1(25.0%)
    Phase 4Post-market surveillance
    3(75.0%)

    Highest Phase Reached

    Phase 4

    Trial Status & Enrollment

    Completion Rate

    100.0%

    3 of 3 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(3)
    Other(1)

    Detailed Status

    Completed3
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 4

    Trials by Phase

    Phase 21 (25.0%)
    Phase 43 (75.0%)

    Trials by Status

    unknown125%
    completed375%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_2

    Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

    NCT00502788
    completedphase_4

    Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C

    NCT00491244
    unknownphase_4

    PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

    NCT01056172
    completedphase_4

    Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

    NCT00948220

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT00502788Phase 2

    Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

    Completed
    NCT00491244Phase 4

    Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C

    Completed
    NCT01056172Phase 4

    PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

    Unknown
    NCT00948220Phase 4

    Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    4